Affiliation:
1. Kulakov National Medical Research Center of Obstetrics, Gynecology and Perinatology
Abstract
Gestational diabetes mellitus (GDM) is one of the most common diseases during pregnancy and increases risks of shortand long-term complications to both mothers and their children. Timely treatment of GDM significantly reduces the specified risks. The development of insulin resistance in pregnancy is associated with increased secretion of maternal and fetoplacental hormones (placental lactogen, estrogens and progesterone, cortisol and prolactin) with increasing gestational age. Thus, GDM develops during pregnancy in patients with insufficient pancreatic function due to progressive hyperglycemia and insulin resistance. Oral glucose tolerance test (OGTT) is the most commonly used test in world practice to establish a diagnosis. In Russia, OGTT is carried out at a gestational age of 24–28 weeks using 75 g of glucose and assessing venous plasma glycemia values at three points: before and 30, 60, and 120 minutes after drinking the glucose solution. However, refusal of patients to complete the test is one of the problems associated with the OGTT. Nausea and vomiting are the most commonly reason for not completing the OGTT. In some cases, patients cannot complete the test due to severe tolerance to a hyperosmolar glucose solution. In such cases, a number of solutions are discussed in the literature, one of which is the possible use of glucose-based compositions comprising flavouring additives, which are allowed for use during pregnancy to improve the tolerability of the OGTT. Improving the tolerability and compliance with the procedure is one of the most important conditions for successful and timely diagnosis.
Reference22 articles.
1. Шестакова ТП, Старостина ЕГ. Диагностика гестационного сахарного диабета. М.: Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского; 2023. 44 с.
2. Belotserkovtseva LD, Kovalenko LV, Kasparova AE, Vasechko TM, Konchenkova EN, Romanova VS. The evolution of the diagnostic criteria of gestational diabetes. Vestnik SurGU. Medicina. 2014;21(3):9–16. (In Russ.) Available at: https://elibrary.ru/tvsvob.
3. Bilous RW, Jacklin PB, Maresh MJ, Sacks DA. Resolving the Gestational Diabetes Diagnosis Conundrum: The Need for a Randomized Controlled Trial of Treatment. Diabetes Care. 2021;44(4):858–864. https://doi.org/10.2337/dc20-2941.
4. Carr D, Gabbe S. Gestational Diabetes: Detection, Management and implications. Clinical Diabetes. 1988;16(1):4–11. Available at: https://web.archive.org/web/20071010144040/http://journal.diabetes.org/clinicaldiabetes/v16n1J-F98/pg4.htm.
5. HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358(19):1991–2002. https://doi.org/10.1056/NEJMoa0707943.